III

Resolution Pharmacology – new therapeutic approaches for the treatment of inflammatory diseases

  • Chair(s):

    Patrícia Silva,
    Researcher in Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

    Professor Mauro Perretti,
    Dean for Research and Research Impact SMD, Queen Mary University of London, London, United Kingdom

  • Session description:

    Development of FPR2 small molecules to treat heart failure: from preclinical to phase I trial
    Dr Ricardo Garcia
    Sr. Principal Scientist, Bristol-Myers Squibb Co., Princeton, NJ, The United States of America

    Advances in antifibrotic therapies for chronic lung diseases
    Dr Patrícia Silva
    Senior Researcher in Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

    Oral communication speaker - to be confirmed in 2022.

    Plasminogen/plasmin: novel players in the resolution of inflammation
    Dr Lirlândia Souza
    Federal University of Minas Gerais, Belo Horizonte, Brazil

    AP1189: a biased agonist for melanocortin receptors in Phase IIa
    Professor Thomas Jonassen
    Syn Act Pharma, Holt, Denmark

  • 00

    days

  • 00

    hours

  • 00

    minutes

  • 00

    seconds

Date

04 Jul 2023

Time

9:45 am - 12:10 pm

Speakers

Leave A Comment